ClinicalTrials.gg
RecruitingNCT05915208Updated Jun 12, 2026

Histiocytic Disorder Follow-up Study

An observational study in Histiocytosis, Langerhans Cell Histiocytosis and Erdheim-Chester Disease, sponsored by University of Alabama at Birmingham. Recruiting at 1 site in United States. Open to participants aged 0 Years to 89 Years. Per ClinicalTrials.gov, last updated 2026-06-12.

Sponsored by University of Alabama at Birmingham · Observational

How we know

From the registry’s dates

  • Started Sep 2022; still recruiting 4 years 2 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Retrospective
Enrollment
6,000
Ages
0 Years to 89 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 14 studies in Histiocytosis with a site in United States — 2 open to participants now, 5 under way, none of them phase 3. Histiocytosis · United States.

Started
2022
the only one that year
Observational
3 of 14
1 open now
Registered
14th of 14
by date

Among the 14 studies in Histiocytosis with a site in United States, this one is the only one that started in 2022, is one of 3 observational ones, and was the 14th registered.

Histiocytosis

25 studies on the registry are indexed under Histiocytosis; 8 are open to participants now.

Browse Histiocytosis studies →

Open to participants now

2 of the 14 studies in Histiocytosis with a site in United States are open now. Recruiting first, the newest first:

All 2 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 4 Histiocytosis studies recruiting now, 3 set no upper age limit and none stop at 75 or younger; 2 take children under 18; none take healthy volunteers.

This study: 0 Years to 89 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 14 studies in Histiocytosis with a site in United States, or all of them as a file.
02

Study summary

The purpose of the study is to describe the burden of chronic health conditions, psychological dysfunction, chronic pain, healthcare utilization, worse health-related quality of life, overall mortality, and cause-specific mortality among individuals with histiocytic disorders

Read the detailed description

Background

Over the last decade, major advances have occurred in histiocytic disorders with the discovery of MAPK-ERK pathway mutations leading to targeted therapeutics using BRAF- and MEK-inhibitors. However, there is a lack of large studies informing the burden of morbidity and mortality among people with histiocytosis. Institutional studies in pediatric LCH suggest that survivors suffer from long-term impairment of health related quality of life, cognitive dysfunction, pituitary dysfunction, and hearing difficulties in 20-50% cases. Studies from the investigative team and others have also shown a high incidence of acute myeloid leukemia and other second primary malignancies in pediatric and adult LCH. Chronic medical conditions may arise as a function of the disease biology or due to cancer therapy, as seen in other hematologic malignancies.

Design

Retrospective cohort study aimed at determining the risk of chronic health conditions and cause-specific mortality in pediatric and adult patients with histiocytic disorders. The study will include patients from the Histiocytosis Association registry and other institutions including UAB (n\~6000). The participants will complete a validated questionnaire capturing details of chronic health conditions, health related quality of life, cognitive/psychological function, and healthcare utilization.

Future directions

The results from our study will be instrumental in formulating follow-up guidelines for histiocytic disorders and developing targeted survivorship programs to improve overall outcomes.

03

Conditions studied

  • Histiocytosis
  • Langerhans Cell Histiocytosis
  • Erdheim-Chester Disease
  • Rosai Dorfman Disease
  • Xanthogranuloma
  • Malignant Histiocytoses

Keywords

  • survivorship
  • long-term
  • targeted therapy
  • second cancer
04

Who can participate

Ages eligible
0 Years to 89 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Individuals with diagnosis of histiocytic disorder are eligible to participate, including family members (next of kin) of deceased individuals.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • diagnosis of histiocytic disorder at any age

    1. Langerhans cell histiocytosis,
    2. Erdheim-Chester disease,
    3. Rosai-Dorfman disease,
    4. Xanthogranuloma,
    5. Mixed histiocytosis
    6. Malignant histiocytosis (Histiocytic sarcoma, langerhans cell sarcoma, interdigitating cell sarcoma)
    7. Hemophagocytic lymphohistiocytosis

Exclusion criteria

Exclusion Criteria:

  • None
05

Study design

Observational model
Cohort
Time perspective
Retrospective
Enrollment
6,000 participants (estimated)
Patient registry
No
06

What researchers measure

Primary outcomes

  1. Chronic health conditions diagnosed after LCH diagnosis graded using the Common Terminology Criteria for Adverse Events (CTCAE), v5.0 (https://ctep.cancer.gov)

    The CTCAE criteria for CHCs distinguishes each acute and chronic condition (including SPMs) in persons with cancer from grades 1 through 4 with unique clinical descriptions of severity (grade 1, mild; grade 2, moderate; grade 3, severe; grade 4, life-threatening/disabling). The main outcome will be the number of distinct CTCAE grade 3-4 conditions among LCH cases compared with unaffected (non-cancer) controls.

    Time frame: From diagnosis of histiocytic disorder to age at completion of survey, assessed up to 200 months

  2. All-cause and cause-specific mortality

    Causes of death will be grouped into primary cancer (LCH)-related mortality (PCRM) and non-primary cancer-related mortality (NPCRM - death from all causes other than the index LCH diagnosis) by two independent investigators.

    Time frame: 2 years preceding death

Secondary outcomes

  1. Factors associated with new-onset morbidity

    We will build a prediction model that has a good discrimination for predicting CHC, SPMs, and psychological outcomes separately using data from the LCH (case) cohort.

    Time frame: From diagnosis to age at completion of survey, assessed up to 200 months

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Sep 2022 (actual). Primary completion is estimated for Jul 2027, 58 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
May 25, 2023
First posted
Jun 22, 2023
StartActual
Sep 1, 2022
Primary completionEst.
Jul 2027
CompletionEst.
Dec 2028
Last update
Jun 12, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 12, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05915208
Responsible party
Gaurav Goyal (Principal Investigator, University of Alabama at Birmingham) — Principal investigator
First posted
Jun 22, 2023
Start date
Sep 1, 2022
Primary completion
Jul 2027 (estimated)
Completion
Dec 2028 (estimated)
Last update
Jun 12, 2026

Study contacts

Gaurav Goyal, MD
Contact
histio@uabmc.edu
1-866-438-1640
Gaurav Goyal, MD
principal investigator · University of Alabama at Birmingham

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion